Basel, Switzerland, 2007/04/12
Genedata have developed a novel analysis workflow to exploit cell based assays in early drug discovery. The company will present the workflow at the forthcoming Annual Society for Biomolecular Screening conference in Montreal, Canada.
Compared to conventional screening technologies, cell based assays provide a more complete picture about the biological effects of chemical compounds. But to exploit these assays in drug discovery, scientists must find efficient ways to extract discovery-relevant information from thousands of high resolution images of cells.
Swiss-based computational firm Genedata is collaborating with imaging technology providers to enhance automation and standardization for the analysis of cell based assays. So far, it has created a robust data exchange format for two-way communication between standard image data formats and Genedata’s analysis system.
Genedata has also produced a web browser based review workflow for accessing microscopy image data at any point during data processing and analysis. The workflow makes it vastly more practical to go back and validate screening results against the original data. This means biologically important information obtained from cell based assays can be identified with greater efficiency.
The presentation at the forthcoming SBS conference shows how this can improve the accuracy and reliability of high content screens of compounds or of so-called small inhibitory RNA’s. Improvements such as this make it more practical and efficient to screen for complex biological effects in a high throughput industrial setting. “This is a software-driven collaboration with technology providers that is bringing added value to cell based screening approaches to drug discovery”, explained Dr. Stephan Heyse, Head of Genedata Screener.
Contact
Genedata AG
Dr. Tobe Freeman
Head, Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244
tobe.freeman@genedata.com
www.genedata.com
Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Tokyo (Japan), Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Taiwan and Singapore. For more information about Genedata, please visit: www.genedata.com.
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Related Files:
download pdf